HEATON has invested in the development of the innovative GYNELLA® Flora product based on tyndallized lactobacilli

HEATON has invested in the development of the innovative GYNELLA® Flora product based on tyndallized (inactivated) lactobacilli to boost natural vaginal immunity in response to the amendment of the EU Regulation on med-ical devices. As a result of the amendment of European legislation, pharmaceutical companies will no longer be able to supply medical devices containing live lactobacilli to EU markets. In response to this measure, HEATON de-cided to invest in the development of a new innovative product that will allow patients to take advantage the potential of the lactobacillus strain in their inactivated i.e., inanimate form.